Regulatory FDA’s ODAC delivers one loss, one win for AstraZeneca PharmaphorumThe FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.OncologyRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaphorum The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant. Oncology Read full story Post navigation Previous: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitationNext: Amgen positions MariTide as potential ‘best monthly’ obesity drug Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026